HARBIN, China, Oct. 4 /PRNewswire-Asia-FirstCall / -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that the Company intends to launch three new therapeutics during the first quarter of 2011. Weikang expects that its new products have the potential to add up to approximately $3.1 million in revenue and up to approximately $1.1 million in net income combined in 2011.
"We are pleased to be able to regularly launch high margin new products that enable us to continue expanding our market penetration and future revenue and net income growth," commented Mr. Yin Wang, Chairman and CEO of Weikang Bio-Technology Group. "Over the past few years our research and development team have been extremely focused on developing a strong pipeline of high-quality, therapeutics to address today's important health issues. In addition, we ensure that our products are produced using the highest quality of natural ingredients and advanced processing technologies for maximum effectiveness."
The new therapeutics have been approved by the State Food and Drug Administration (SFDA). A brief description of the new therapeutics expected to be launched in first quarter 2011 is listed below:
About Weikang Bio-Technology Group Co., Inc.Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang. For more information, please visit http://www.weikangbio.com.
Safe Harbor StatementThis press release contains certain statements that may include "forward looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.Company contact:Ren Hu, VP of FinanceWeikang Bio-Technology Group Co., Inc.US Tel: (201) 887-0415China cell: 13718728163Email: firstname.lastname@example.orgInvestors Relation contacts:John Marco, Partner, Elite IRTel: +1-310-819-2948Email: John.email@example.comLeslie J. Richardson, Partner, Elite IRTel: +852-3183-0283Email: Leslie.firstname.lastname@example.org
|SOURCE Weikang Bio-Technology Group Co., Inc.|
Copyright©2010 PR Newswire.
All rights reserved